




. PTH(parathyroid hormone), VMA(vanillylman -  
delic acid), metanephrine, epinephrine, norepinephrine

2 × 3 cm


가



**Fig. 1.** Neck CT shows 2×3 cm sized heterogeneous and co-  
ntrast enhanced mass is visible on left thyroid lobe (arrow).



**Fig. 2.** Pathological appearance of the tumor in the left lobe,  
showing medullary carcinoma of the thyroid (H-E stain, × 100).  
The neoplastic cells were spindle-shaped or polygonal with li-  
ghtly eosinophilic cytoplasm.



**Fig. 3.** Pathological appearance of the tumor in the right lobe,  
showing papillary carcinoma of the thyroid (arrow) (H-E stain,  
× 40).

(Fig. 1).

2000 1

26

4.5 × 2.5 cm

(Fig. 2),

2 mm

(Fig. 3). 1

CEA

, Calcitonin 102.8 pg/ml 가

1.5 3

30 mCi <sup>131</sup>I

, 3

39.7 pg/ml

가 33

2

2)

3)

가 35%

4)

가 가

RET protoonc -

ogene 가

5)

100%

PTC oncogene

(C )

(thyroglobulin)

(thyroid hormone)

가

가

가 6)7)

4

5

(ultimobranchial body)

doderm)

(en -

8)

가

가

thyrotropin C

가  
가  
(  
)<sup>10)</sup>  
가  
가  
가  
level IV, VI  
(<sup>11)</sup><sup>12)</sup>  
cm)  
가  
가  
50%  
가  
가  
TI - 201, Tc - 99m DMSA, <sup>131</sup>I - MIBG  
CEA <sup>131</sup>I  
(monoclonal antibody)<sup>10)</sup>, PET

## REFERENCES

- 1) Marsh DJ, Learoyd DL, Robinson BG. *Medullary thyroid carcinoma: Recent Advances and Management Update*. *Thyroid* 1995; 5:407-24.
- 2) Kobayashi K, Teramoto S, Maeta H, Ishiguro S, Mori T, Horie Y. *Simultaneous occurrence of medullary carcinoma and papillary carcinoma of the thyroid*. *J Surg Oncol* 1995;59:276-9.
- 3) Pastolero GC, Coire CI, Asa SL. *Concurrent medullary and papillary carcinoma of thyroid with lymph node metastases. A collision phenomenon*. *Am J Surg Pathol* 1996;20:245-50.
- 4) Kaplan MM. *Progress in thyroid cancer*. *Endocrinol Metab Clin North Am* 1990;19:469-78.
- 5) Santoro M, Rosati R, Grieco M, Berlingieri MT, D'Amato GL, de Frandis V, et al. *The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas*. *Oncogene* 1990;5:1595-8.
- 6) Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, et al. *A new oncogene in human thyroid papillary carcinoma and their lymphnodal metastases*. *Nature* 1987;328:170-2.
- 7) Ljungberg O, Bondeson L, Bondeson AG. *Differentiated thyroid carcinoma, intermediate type: a new tumor entity with features of follicular and parafollicular cell carcinoma*. *Hum Pathol* 1984; 15:218-28.
- 8) Ljungberg O, Ericsson UB, Bondeson L, Thorell J. *A compound follicular-parafollicular cell carcinoma of the thyroid: a new tumor entity?*. *Cancer* 1983;52:1053-61.
- 9) Triggs SM, Williams ED. *Experimental carcinogenesis in the thyroid follicular and C cells*. *Acta Endocrinol (Copenh)* 1977;85: 84-92.
- 10) Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. *Medullary Thyroid Carcinoma*. *Cancer* 2000;88:1139-48.
- 11) Koh JW, Lee JS, Kim SK, Jin YM. *A Case of familial medullary thyroid carcinoma*. *Kor J Otolaryngol* 1997;40:1675-80.
- 12) Kim SH, No HS, Moon JH, Kim JS, Hwang DJ, Seo JM. *The Clinical analysis of medullary thyroid carcinoma: 10 Cases*. *Kor J Otolaryngol* 1999;15:222-5.